Hepatocellular carcinoma: Response to TACE assessed with semiautomated volumetric and functional analysis of diffusion-weighted and contrast-enhanced MR imaging data

Radiology

Volumn 260, Issue 3, 2011, Pages 752-761

  Bonekamp, Susanne ^a   Jolepalem, Prashant ^a   Lazo, Mariana ^b   Gulsun, Mehmet Akif ^c   Kiraly, Atilla P ^c   Kamel, Ihab R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c SIEMENS CORPORATE RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GADOLINIUM PENTETATE;

ADULT; AGED; APPARENT DIFFUSION COEFFICIENT; ARTICLE; AUTOMATION; CANCER SIZE; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER CELL CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PHYSICAL PARAMETERS; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; TREATMENT RESPONSE; VENOUS ENHANCEMENT;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CONTRAST MEDIA; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE ENHANCEMENT; IMAGING, THREE-DIMENSIONAL; LIVER DISEASES; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84860391243     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11102330     Document Type: Article

References (40)

1. American Cancer Society. Cancer Statistics 2009, Cancer Facts & Figures 2009. Atlanta, Ga: American Cancer Society, 2010.
2. Carr B.I. Hepatic artery chemoembolization for advanced stage HCC: Experience of 650 patients. Hepatogastroenterology 2002;49(43):79-86. (Pubitemid 34289490)
3. Chapman W.C., Majella Doyle M.B., Stuart J.E., et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248(4):617-625.
4. Therasse P., Eisenhauer E.A., Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006;42(8):1031-1039.
5. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228-247.
6. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92(3):205-216.
7. Padhani A.R., Leach M.O. Antivascular cancer treatments: Functional assessments by dynamic contrast-enhanced magnetic resonance imaging. Abdom Imaging 2005;30(3):324-341. (Pubitemid 40898066)
8. Mannelli L., Kim S., Hajdu C.H., Babb J.S., Clark T.W., Taouli B. Assessment of tumor necrosis of hepatocellular carcinoma after chemoembolization: Diffusion-weighted and contrast-enhanced MRI with histopathologic correlation of the explanted liver. AJR Am J Roentgenol 2009;193(4):1044-1052.
9. Kim S., Mannelli L., Hajdu C.H., et al. Hepatocellular carcinoma: Assessment of response to transarterial chemoembolization with image subtraction. J Magn Reson Imaging 2010;31(2):348-355.
10. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35(3):421-430. (Pubitemid 32844200)
11. Kamel I.R., Liapi E., Reyes D.K., Zahurak M., Bluemke D.A., Geschwind J.F. Unresectable hepatocellular carcinoma: Serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009;250(2):466-473.
12. Kamel I.R., Reyes D.K., Liapi E., Bluemke D.A., Geschwind J.F. Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2007;18(1 Pt 1):49-56. (Pubitemid 46616678)
13. Kamel I.R., Bluemke D.A., Eng J., et al. The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma. J Vasc Interv Radiol 2006;17(3):505-512. (Pubitemid 44318722)
14. Padhani A.R., Miles K.A. Multiparametric imaging of tumor response to therapy. Radiology 2010;256(2):348-364.
15. Padhani A.R., Khan A.A. Diffusion-weighted (DW) and dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for monitoring anticancer therapy. Target Oncol 2010;5(1):39-52.
16. Padhani A.R., Liu G., Koh D.M., et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: Consensus and recommendations. Neoplasia 2009;11(2):102-125.
17. Kamel I.R., Bluemke D.A., Ramsey D., et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 2003;181(3):708-710. (Pubitemid 37021839)
18. Patterson D.M., Padhani A.R., Collins D.J. Technology insight: Water diffusion MRI - a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol 2008;5(4):220-233. (Pubitemid 351493681)
19. Enquobahrie A.A., Reeves A.P., Yankelevitz D.F., Henschke C.I. Automated detection of small pulmonary nodules in whole lung CT scans. Acad Radiol 2007;14(5):579-593. (Pubitemid 46551756)
20. Kostis W.J., Yankelevitz D.F., Reeves A.P., Fluture S.C., Henschke C.I. Small pulmonary nodules: Reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT. Radiology 2004;231(2):446-452. (Pubitemid 38552903)
21. Wormanns D., Kohl G., Klotz E., et al. Volumetric measurements of pulmonary nodules at multi-row detector CT: In vivo reproducibility. Eur Radiol 2004;14(1):86-92. (Pubitemid 38181058)
22. Revel M.P., Bissery A., Bienvenu M., Aycard L., Lefort C., Frija G. Are two-dimensional CT measurements of small noncalcified pulmonary nodules reliable? Radiology 2004;231(2):453-458. (Pubitemid 38552904)
23. Marten K., Auer F., Schmidt S., Kohl G., Rummeny E.J., Engelke C. Inadequacy of manual measurements compared to auto mated CT volumetry in assessment of treatment response of pulmonary metastases using RECIST criteria. Eur Radiol 2006;16(4):781-790. (Pubitemid 43380236)
24. Van Hoe L., Van Cutsem E., Vergote I., et al. Size quantification of liver metastases in patients undergoing cancer treatment: Reproducibility of one-, two-, and three-dimensional measurements determined with spiral CT. Radiology 1997;202(3):671-675. (Pubitemid 27093435)
25. Puesken M., Juergens K.U., Edenfeld A., et al. Accuracy of liver lesion assessment using automated measurement and segmentation software in biphasic multislice CT (MSCT) [in German]. Rofo 2009;181(1):67-73.
26. Keil S., Behrendt F.F., Stanzel S., et al. Semiautomated measurement of hyperdense, hypodense and heterogeneous hepatic metastasis on standard MDCT slices: Comparison of semi-automated and manual measurement of RECIST and WHO criteria. Eur Radiol 2008;18(11):2456-2465.
27. Keil S., Plumhans C., Behrendt F.F., et al. Semiautomated quantification of hepatic lesions in a phantom. Invest Radiol 2009;44(2):82-88.
28. Gulsun M.A., Weiss C.R., Strecker R., Meredith G., Kamel IR A new tool for volumetric and functional analysis of hepatic tumors monitored with multi-modal MRI [abstr] In: Proceedings of the Seventeenth Meeting of the International Society for Magnetic Resonance in Medicine Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 2009;2876.
29. Chefd'Hotel C, Hermosillo G, Faugeras O. Flows of diffeomorphisms for multimodal image registration. 2002 IEEE International Symposium on Biomedical Imaging; 753. July 7-10, 2002.
30. Grady L. Random walks for image segmentation. IEEE Trans Pattern Anal Mach Intell 2006;28(11):1768-1783. (Pubitemid 46405425)
31. Galbán C.J., Chenevert T.L., Meyer C.R., et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat Med 2009;15(5):572-576.
32. Hamstra D.A., Galbán C.J., Meyer C.R., et al. Functional diffusion map as an early imaging biomarker for high-grade glioma: Corre lation with conventional radiologic response and overall survival. J Clin Oncol 2008;26(20):3387-3394.
33. Moffat B.A., Chenevert T.L., Meyer C.R., et al. The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006;8(4):259-267.
34. Padhani A.R., Koh D.M. Diffusion MR imaging for monitoring of treatment response. Magn Reson Imaging Clin N Am 2011;19(1):181-209.
35. Suzuki C., Jacobsson H., Hatschek T., et al. Radiologic measurements of tumor response to treatment: Practical approaches and limitations. RadioGraphics 2008;28(2):329-344.
36. Forner A., Ayuso C., Varela M., et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: Are response evaluation criteria in solid tumors reliable? Cancer 2009;115(3):616-623.
37. Vossen J.A., Buijs M., Geschwind J.F., et al. Diffusion-weighted and Gd-EOB-DTPA-contrast-enhanced magnetic resonance imaging for characterization of tumor necrosis in an animal model. J Comput Assist Tomogr 2009;33(4):626-630.
38. Ross B.D., Moffat B.A., Lawrence T.S., et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003;2(6):581-587.
39. Deng J., Miller F.H., Rhee T.K., et al. Diffusion-weighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 2006;17(7):1195-1200. (Pubitemid 44318703)
40. Rhee T.K., Naik N.K., Deng J., et al. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: Comparison of diffusion-weighted functional MR imaging with anatomic MR imaging. J Vasc Interv Radiol 2008;19(8):1180-1186.